ADVERTISEMENT
Consumer
CRN’s attorneys ask Second Circuit for en banc review of a three-judge panel’s denial of its appeal of 2024 decision in district court rejecting motion for preliminary injunction against enforcement of New York state law age-restricting sales of weight loss and muscle building supplements.
Agency intends to use information from comments to guide its planning for a public meeting during 2026, according to a Federal Register notice. A GAO report is due in a year to Congress profiling FDA’s progress on making more drugs available nonprescription through OTC switch applications.
Lawmakers in IL, MA and NJ as well as MI consider proposals as firms marketing weight loss and bodybuilding supplements in New York already are subject to first-ever state law limiting sales of products to consumers 18 and older.
Canadian firm states in 2026 forecast that its research, including consumer surveys and sales data, shows a majority of consumers, 65%, are not only familiar with the benefits of prebiotics but also interested in the ingredients, 55%.
Regardless of THC level and even though the US hemp product marketplace is growing, FDA regulations prohibit the botanical’s use as a dietary ingredient or food additive because it’s been studied or approved for use as a drug in the US.
After using supplements from third-party providers for personalized nutrition programs it offered to patients at wellness clinics it operated, Designs for Health has shifted to focus entirely on providing supplements to healthcare practitioners.
Three-judge Second Circuit panel rejects CRN’s argument that New York General Business Law Section 391-oo, effective since April 2024 as first in US to prohibit sales of certain supplements to consumers under 18, violates First Amendment rights of supplement marketers.
But the Senate’s reduction would not be as much as the House of Representatives and President Trump proposed earlier this year, which is likely a win for the agency.
Virgin Scent didn’t respond to NAD attorneys’ “repeated outreach attempts” asking for evidence supporting ad claims for Artnaturals NAD+ challenged by another NAD+ supplement marketer, Reus Research.
MultiBurn supplement launch “is creating kind of a new focus I would say around weight loss, where quite honestly, we’ve been probably more of a healthy active lifestyle,” says CEO Stephan Gratziani. Pro2Col app for personalized wellness launching before January.
Perrigo pauses $240m spending planned for formula business as it considers options to be in better position to boost growth on OTC drugs. “Problems make formula manufacturing’s “long-term fit alongside our faster-growing, higher-cash-yielding consumer health OTC portfolio less strategic,” says presi
Dave Wendland retires after 34 years at HRG; AHPA science chief Holly Johnson earns WIN Guiding Star; Strategy, people leads for Vitamin Shoppe; CDMO Kenox appoints R&D, manufacturing VP; and contract manufacturer Radienz adds customer chief.











